Yuma-area residents may be able to participate in COVID-19 research
Yuma Regional Medical Center (YRMC) recently joined a prestigious international clinical trial that is researching a potential treatment for COVID-19 that could help to reduce complications and hospitalizations due to the virus or even save lives in Yuma and around the world.
The clinical trial, called COLCORONA, is exploring the potential to treat COVID-19 patients by using a well-known, widely available and inexpensive anti-inflammatory medication called colchicine. The drug is commonly used to treat conditions such as gout, pericarditis and Familial Mediterranean Fever.
In addition to Yuma, the clinical trial’s other locations in the United States are: The New York Tri-State Area, San Francisco, Los Angeles, Miami, Houston, Dallas, Phoenix, Jacksonville, Rochester, Greenville, Chapel Hill and Bakersfield.
People living within 40 miles of Yuma who meet certain patient criteria may be able to participate in the COLCORONA trial, which would provide the medication for free. Treatment would take place in the patient’s home. Participants do not have to be YRMC patients.
The clinical trial is led by a highly respected medical team at the Montreal Heart Institute and the Montreal Health Innovations Coordinating Center in Canada. The research is being supported by doctors throughout Canada, United States, Spain, Brazil and South Africa. Funding for the clinical trial has been provided by the Government of Quebec, the US National Institutes of Health and the Bill & Melinda Gates Foundation.
“By participating in this clinical trial, we are continuing to help advance health care and aid those seeking a treatment for the potentially devastating health complications caused by COVID-19,” says Dr. Oday Al-Rabadi, the principal investigator for the trial at YRMC.
COLCORONA represents one of many clinical trials currently being overseen by Yuma Regional Medical Center Institutional Research. (For more information please visit yumaregional.org/Medical-Services/Clinical-Trials)
COLCORONA’s participants are recently diagnosed COVID-19 patients or people who are currently showing symptoms and have a household member diagnosed with COVID-19. Participants for the Yuma portion of the study must be over the age of 40 and live in Arizona.
Once enrolled, the medicine or placebo is delivered directly to participants’ homes at no cost. Patients will have the support of a dedicated health care team 24/7 for any questions. The study’s staff will contact patients directly via phone or video visits for follow-up communication.
This research is one of just a few clinical trials that tests a treatment at the time of diagnosis against a placebo while the patients are caring for themselves at home.
“Extending COLCORONA’s locations to include Yuma Regional Medical Center as a site allows us to reach even more diverse populations across the country,” says Jean-Claude Tardif, M.D., director of the Research Centre at the Montreal Heart Institute (MHI). Dr. Tardif is a professor of medicine at the University of Montreal, and COLCORONA principal investigator.
Recent COVID-19 statistics in Arizona point to the need for finding a good treatment. State health officials stress that the global pandemic has recently not ended. Officials reported Monday that Arizona on that day alone saw 801 new cases of COVID-19, as identified cases of positive diagnosis top 238,964 and continue to climb in our state.
Patients and physicians who are interested in COLCORONA may call the study hotline at 1-877-536-6837 or visit www.colcorona.net.
About the COLCORONA Trial
COLCORONA is a contact-free, at-home, randomized, double-blind, placebo-controlled study conducted in the United States, Canada, South America, Europe, and South Africa. COLCORONA is coordinated by the Montreal Health Innovations Coordinating Center (MHICC) and funded by the Government of Quebec, the Bill & Melinda Gates Foundation, the National Heart, Lung, and Blood Institute (NHLBI) of the United States National Institutes of Health (NIH). Montreal philanthropist Sophie Desmarais, Pharmascience, CGI, and DACIMA are also collaborators of COLCORONA.
The Montreal Heart Institute and its partners worldwide would like to thank all the patients and investigators for their continued participation in the COLCORONA study. For more information about the study, visit www.colcorona.net.
About the Montreal Heart Institute
Founded in 1954, the Montreal Heart Institute constantly aims for the highest standards of excellence in the cardiovascular field through its leadership in clinical and basic research, ultra-specialized care, professional training, and prevention. It houses the largest research center in Canada, the largest cardiovascular prevention center in the country, and the largest cardiovascular genetics center in Canada. The Institute is affiliated with the University of Montreal and has more than 2000 employees, including 245 doctors and more than 85 researchers.
About the Montreal Health Innovations Coordinating Center (MHICC)
The Montreal Health Innovations Coordinating Center (MHICC) is a leading academic clinical research organization and an integral part of the Montreal Heart Institute (MHI). The MHICC possesses an established network of collaborators in over 4500 clinical sites in more than 40 countries. It has specific expertise in precision medicine, low-cost high-quality clinical trials, and drug repurposing.
About Yuma Regional Medical Center
Yuma Regional Medical Center (YRMC) is a 406-bed, not-for-profit hospital dedicated to providing outstanding medical care to the residents of Yuma and the surrounding communities in southwestern Arizona. The YRMC team includes more than 2,500 employees, 300 medical providers and hundreds of volunteers who work closely together to create a welcoming, caring and compassionate environment for patients and their families.